HC Wainwright & Co. Reiterates Neutral on Bolt Biotherapeutics
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Neutral rating on Bolt Biotherapeutics (NASDAQ:BOLT).
August 15, 2024 | 9:52 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Edward White has reiterated a Neutral rating on Bolt Biotherapeutics.
The reiteration of a Neutral rating suggests that the analyst does not see significant short-term upside or downside potential for Bolt Biotherapeutics. This is likely to result in a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100